Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Biocept Inc. (BIOC)

3.02   -0.01 (-0.33%) 01-21 17:43
Open: 3.01 Pre. Close: 3.03
High: 3.1 Low: 2.9805
Volume: 144,669 Market Cap: 51M
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor nucleic acid assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. Its Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from circulating tumor DNA; and Target-Selector CTC and molecular platforms provide biomarker detection and monitoring capabilities. In addition, it offers laboratory services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians. Further, it is developing PCR-based assays for detecting the COVID-19 virus. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. It has a partnership with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.12 - 3.15 3.15 - 3.168
Low: 2.917 - 2.956 2.956 - 2.979
Close: 2.976 - 3.039 3.039 - 3.077

Technical analysis

as of: 2022-01-21 4:25:07 PM
Stoxline posted a SELL today, upgraded from strong sell. Downward movement continues, but could change at any time.
Target: Six months: 4.25     One year: 4.72
Support: Support1: 2.98    Support2: 2.48
Resistance: Resistance1: 3.64    Resistance2: 4.04
Pivot: 3.48
Moving Average: MA(5): 3.13     MA(20): 3.54
MA(100): 3.79     MA(250): 4.42
MACD: MACD(12,26): -0.19     Signal(9): -0.12
Stochastic oscillator: %K(14,3): 2.72     %D(3): 4.23
RSI: RSI(14): 29.28
52-week: High: 8.38  Low: 2.98  Change(%): -50.6
Average Vol(K): 3-Month: 236  10-Days: 191

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
BIOC has closed above bottom band by 9.7%. Bollinger Bands are 126.9% wider than normal. The large width of the bands suggest high volatility as compared to Biocept Inc.'s normal range. The bands have been in this wide range for 3 bars. This is a sign that the current trend might continue.

Headline News

Fri, 21 Jan 2022
NA Proactive news snapshot: Psyence Group, Red Pine Exploration, Biocept, Contakt World Technologies UPDATE ... - Proactive Investors USA

Fri, 21 Jan 2022
NA Proactive news snapshot: Red Pine Exploration, Biocept, Contakt World Technologies, Information Services Corporation ... - Proactive Investors

Fri, 21 Jan 2022
Biocept is changing the way physicians examine blood work for their cancer patients and doing coronavirus testing - Proactive Investors USA

Fri, 21 Jan 2022
Biocept Reports an Increase in COVID-19 RT-PCR Testing Volume with Spread of the Omicron Variant - Business Wire

Fri, 07 Jan 2022
Has Biocept, Inc. (BIOC) Outpaced Other Medical Stocks This Year? - Nasdaq

Tue, 04 Jan 2022
Biocept to Present at the H.C. Wainwright BioConnect Virtual Conference on January 10 - Yahoo Finance

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Outperform
Return on Equity: Neutral Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Diagnostics & Research
Shares Out. (M) 17
Shares Float (M) 17
% Held by Insiders 0.04
% Held by Institutions 12.08
Shares Short (K) 402
Shares Short P. Month (K) 526

Stock Financials

EPS 0.219
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 2.400
Profit Margin 4.71
Operating Margin 5.15
Return on Assets (ttm) 4.5
Return on Equity (ttm) 10.1
Qtrly Rev. Growth 165.2
Gross Profit (p.s.) 0.363
Sales Per Share 3.906
EBITDA (p.s.) 0.280
Qtrly Earnings Growth
Operating Cash Flow (M) 1
Levered Free Cash Flow (M) -3

Stock Valuations

PE Ratio 13.79
PEG Ratio
Price to Book value 1.26
Price to Sales 0.77
Price to Cash Flow

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date 2020-09-07
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.